Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Cash from Financing Activities: 2021-2025

Historic Cash from Financing Activities for Prime Medicine (PRME) over the last 4 years, with Sep 2025 value amounting to $144.8 million.

  • Prime Medicine's Cash from Financing Activities rose 275.85% to $144.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.0 million, marking a year-over-year decrease of 23.01%. This contributed to the annual value of $195.9 million for FY2024, which is 29804.73% up from last year.
  • As of Q3 2025, Prime Medicine's Cash from Financing Activities stood at $144.8 million, which was up 73,378.68% from $197,000 recorded in Q2 2025.
  • In the past 5 years, Prime Medicine's Cash from Financing Activities ranged from a high of $184.1 million in Q4 2022 and a low of -$1.3 million during Q1 2022.
  • For the 3-year period, Prime Medicine's Cash from Financing Activities averaged around $31.6 million, with its median value being $197,000 (2025).
  • As far as peak fluctuations go, Prime Medicine's Cash from Financing Activities crashed by 99.89% in 2023, and later soared by 231,263.24% in 2024.
  • Over the past 5 years, Prime Medicine's Cash from Financing Activities (Quarterly) stood at -$1.1 million in 2021, then soared by 17,049.63% to $184.1 million in 2022, then crashed by 99.89% to $194,000 in 2023, then plummeted by 99.48% to $1,000 in 2024, then spiked by 275.85% to $144.8 million in 2025.
  • Its Cash from Financing Activities was $144.8 million in Q3 2025, compared to $197,000 in Q2 2025 and $6.0 million in Q1 2025.